WallStSmart

Arcutis Biotherapeutics Inc (ARQT)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 61% more annual revenue ($606.42M vs $376.07M). INSM leads profitability with a -2.1% profit margin vs -4.3%. INSM earns a higher WallStSmart Score of 39/100 (F).

ARQT

Hold

36

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: -2.08

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARQT1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
81.5%10/10

Revenue surging 81.5% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ARQT4 concerns · Avg: 3.0/10
Price/BookValuation
14.8x4/10

Trading at 14.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-9.3%2/10

ROE of -9.3% — below average capital efficiency

Altman Z-ScoreHealth
-2.082/10

Distress zone — elevated risk

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ARQT

The strongest argument for ARQT centers on Revenue Growth. Revenue growth of 81.5% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ARQT

The primary concerns for ARQT are Price/Book, EPS Growth, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ARQT profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

ARQT carries more volatility with a beta of 1.74 — expect wider price swings.

ARQT is growing revenue faster at 81.5% — sustainability is the question.

ARQT generates stronger free cash flow (26M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arcutis Biotherapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?